Historically, the terms young-onset and early-onset Parkinson’s disease have been used for research of Parkinson’s disease that presents before the typical age (after the age of 50).1 The International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson’s Disease have recommended that the term ‘early-onset Parkinson’s disease’ be used, and that it refers to people with Parkinson’s disease symptom onset from 21 to under 50 years of age. Juvenile PD refers to the onset of PD prior to the age of 21 years.1

Studies suggest that, in general, people with early-onset PD tend to experience slower progression of symptoms than patients with later onset1

file_download Download in HQ

Related content

image Image Graphic showing extracellular, multimerization, and intracellular targets of alpha-synuclein for therapeutic intervention in Parkinson’s disease
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Chart showing progression of functional decline in Parkinson’s disease with different treatment approaches, from symptomatic benefit to disease modification.
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Diagram showing how COMT inhibitors block the conversion of L-DOPA to 3-OMD, enhancing dopamine levels in the synapse in Parkinson’s disease.
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease